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Abstract: Recent ﬁ  ndings in animal models of paraplegia suggest that speciﬁ  c nonbenzodiazepine 
anxiolytics may temporarily restore locomotor functions after spinal cord injury (SCI). Experi-
ments using in vitro models have revealed, indeed, that selective serotonin receptor (5-HTR) 
ligands such as 5-HTR1A agonists, known as relatively safe anxiolytics, can acutely elicit episodes 
of rhythmic neuronal activity refered to as ﬁ  ctive locomotion in isolated spinal cord preparations. 
Along the same line, in vivo studies have recently shown that this subclass of anxiolytics can 
induce, shortly after systemic administration (eg, orally or subcutaneously), some locomotor-like 
hindlimb movements during 45–60 minutes in completely spinal cord-transected (Tx) rodents. 
Using ‘knock-out’ mice (eg, 5-HTR7-/-) and selective antagonists, it has been clearly established 
that both 5-HTR1A and 5-HTR7 were critically involved in mediating the pro-locomotor effects 
induced by 8-OH-DPAT (typically referred to as a 5-HTR1A agonist) in Tx animals. Taken 
together, these in vitro and in vivo data strongly support the idea that 5-HTR1A agonists may 
eventually become constitutive elements of a novel ﬁ  rst-in-class combinatorial treatment aimed 
at periodically inducing short episodes of treadmill stepping in SCI patients.
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Introduction
Spinal cord injury (SCI) generally causes permanent disability or loss of movement 
(paralysis) and sensation below the site of the injury leading either to paraplegia 
(thoracic level-injury) or tetraplegia (cervical level-injury). It is well established also 
that many SCI patients will develop anxiety and depression problems as well as other 
severe health complications such as obesity, type II diabetes, cardiovascular diseases, 
hormone dysregulation, muscle and bone loss, immune system deﬁ  ciencies and life-
threatening infections (Bauman et al 1999; Bauman and Spungen 2000; Cruse et al 
2000). No pharmacological treatment is currently available to treat these so-called 
secondary health complications. In turn, the beneﬁ  ts of regular exercise training on 
secondary health complications and the quality of life are increasingly documented 
especially in incomplete SCI patients (Heath and Fentem 1997; Hicks et al 2003; Ditor 
et al 2003; Martin Ginis et al 2008; Ditor et al 2005). However, exercise training has 
remained difﬁ  cult and is poorly adapted for people with a complete SCI (absolutely 
no voluntary motor control) who represent 40%–45% of all SCI cases in the United 
States (National Spinal Cord Injury Statistical Center). Experiments using animal 
models of SCI have recently offered hope for complete SCI patients. Researchers 
have recently found in completely spinal cord-transected (Tx) rodents that 5-HTR1A 
agonists, normally used as anxiolytics, can also partially re-activate lumbar spinal cord 
networks that control locomotion (ie, typically referred to as central pattern generator 
or CPG)(Antri et al 2003, 2005; Landry et al 2006). This breakthrough ﬁ  nding may 
contribute to the development of a ﬁ  rst-in-class drug treatment as ‘CPG activator’ that 
could elicit episodes of exercise training in complete SCI individuals.Neuropsychiatric Disease and Treatment 2008:4(4) 760
Guertin
The 5-HT system
Serotonin (5-hydroxytryptamine or 5-HT) is an important 
endogenous monoamine neurotransmitter found in the 
central nervous system (ie, CNS: the brain and spinal cord), 
peripheral systems (eg, gastrointestinal tract), and plants. In 
the CNS, 5-HT is mainly synthesized by specialized neurons 
in the brainstem (ie, raphe nucleus and parapyramidal region) 
that send projections throughout the brain as well as in the 
spinal cord as far as into the lumbar and sacral segments 
(Hochman et al 2001). This system has clearly been shown to 
play a determinant role in functions and behaviors such as in 
body temperature, anger, mood, sleep, and sexual functions. 
The release of 5-HT by this system is known to inﬂ  uence 
the activity of other neurons via 14 genetically, pharmaco-
logically and functionally distinct 5-HT receptors (5-HTR) 
belonging to seven families termed 5-HTR1 through 5-HT7 
(Barnes and Sharp 1999; Fink and Gothert 2007).
The 5-HT1A receptor subtype
As for all 5-HTR subtypes (except 5-HTR3), the 5-HTR1A is a 
metabotropic receptor that activates cascades of intracellular 
events (Barnes and Sharp 1999). The receptor is localized 
both pre- and postsynaptically (Miquel et al 1992; Radja et al 
1992) and is normally negatively coupled (ie, at least the 
presynaptic one) to adenylyl cyclase via Gi-protein activation 
(Albert et al 1996) and K+ channel opening at least in the 
brain (Clarke et al 1996). In the spinal cord, 5-HTR1A label-
ing using [3H] 8-OH-DPAT (5-HTR1A agonist) has revealed 
expression in laminae I-IV (dorsal horn) and X (intermediate 
zone) in cats (Giroux et al 1999). In situ hybridization has 
also revealed 5-HTR1A expression in all gray matter laminae 
with stronger labelling levels in the dorsal horn and interme-
diate zone in mice (Landry et al 2006). In both cats and mice, 
increased 5-HT1A receptor expression has been detected in 
lumbar spinal cord segments shortly after a low-thoracic Tx 
(Giroux et al 1999; Landry et al 2006). There is compelling 
evidence associating the effects mediated by 5-HTR1A in 
the brain to antidepressant and anxiolytic actions (Gordon 
and Hen 2004). However, its speciﬁ  c role in the spinal cord 
has remained unclear, although recent data have provided 
evidence of a role in sexual functions (Giuliano and Clem-
ent 2006) and pain (Mico et al 2006). Experiments in turtle 
isolated spinal cord preparations have revealed 5-HTR1A on 
the cellular membrane of hindlimb motoneurons whose acti-
vation leads to increased neuronal excitability via inhibition 
of a leak current (Perrier et al 2003). This ﬁ  nding strongly 
suggests that pre- and postsynaptic 5-HTR1A-mediated 
mechanisms are different (eg, presynaptic inhibition in the 
brain versus postsynaptic excitation in the spinal cord). 
However, spinal 5-HTR1A were not believed until recently 
to be specifically associated with locomotor functions. 
Although, preliminary data from in vitro preparations have 
reported early evidence of some role for 5-HTR1A agonists 
in locomotion (Cazalets et al 1992; Hochman et al 2001), 
a clear demonstration of their effects on spinal locomotor 
networks has been provided (Antri et al 2003) and attributed 
only recently to 5-HTR1A and 5-HTR7 receptor-mediated 
actions (Landry et al 2006) which are described in detail in 
the following sections.
Spinal locomotor networks
The existence of a CPG and its role in locomotor pattern and 
rhythm generation has been shown in all classes of vertebrate 
species. In the 1970s, Grillner was the ﬁ  rst to demonstrate 
its existence in mammalian species, when reporting that 
locomotor activity in hindlimb motor nerves could be acutely 
induced following L-DOPA (noradrenaline/dopamine pre-
cursor) administration (iv) in deafferented and low-thoracic 
Tx cats (Grillner and Zangger 1979). These experiments 
have clearly established that a network (or several) of suble-
sional neurons (caudal to the 12th thoracic segment) referred 
to as CPG neurons displayed the capacity of generating 
the basic signals for walking even in complete absence of 
supraspinal inputs and phasic inputs from peripheral nerves 
(see also preliminary evidence from Graham-Brown 1911). 
Nonetheless, a signiﬁ  cant role for peripheral afferent inputs 
to CPG activation and/or modulation has also been shown 
since greater effects were found in nondeafferented animals 
placed on a motorized treadmill (Grillner and Zangger 
1979). A clear demonstration of its existence in humans has 
remained difﬁ  cult since only data from an entirely deaffer-
ented and complete SCI patients would satisfy all criteria. 
Nonetheless, in the 1990s, Calancie and colleagues have 
reported evidence suggesting the existence of a CPG in a 
chronic tetraplegic patient (Calancie et al 1994). Although 
not completely SCI, that patient was shown, once lying 
down on a table, to spontaneously display locomotor-like 
movements in the lower limbs. More convincing data were 
reported a few years later by Dimitrijevic and colleagues 
(1998) who showed locomotor-like movements induced 
by epidural stimulation of the spinal cord (ie, lumbar seg-
ments) in complete paraplegic subjects. Those results have 
strongly suggested the existence of critical CPG elements 
in the lumbar or thoraco-lumbar area of the spinal cord in 
humans. Although a contribution from peripheral inputs 
(eg, proprioceptors, skin receptors, etc.) was possible, this Neuropsychiatric Disease and Treatment 2008:4(4) 761
Anxiolytics for functional recovery in paralytics
series of experiments has clearly shown that spinal stepping 
is possible even in complete absence of inputs from the brain. 
During the same period, automatic air-stepping (in com-
pletely suspended subjects) has been successfully induced 
in healthy persons following tonic muscle vibration which 
may also partially support the idea of a CPG (activated by 
afferent inputs) in humans (Gurﬁ  nkel et al 1998). Prior to 
those studies, preliminary evidence of a CPG was found 
in a complete SCI patient who developed myoclonus and 
leg movements resembling locomotion (eg, low frequency, 
rhythmic and bilaterally alternating; Bussel et al 1988. See 
Illis 1995; Nicol et al 1995 for additional evidence).
Anxiolytic effects induced 
by 5-HTR1A agonists
Typically used for short-term relief of anxiety, antidepres-
sants and anxiolytics are generally devided into two groups, 
benzodiazepines and nonbenzodiazepines. Medications of 
the latter group are increasingly prescribed since compel-
ling evidence suggests that they lack the sedation- and 
dependence-related side effects associated with benzodiaz-
epines. 5-HTR1A agonist-induced anxiolytic/antidepressive 
effects are believed to be mainly mediated by a progressive 
desensitization of presynaptic autoreceptors in the raphe 
nucleus leading to a reduction of autoreceptor-mediated 
neuronal inhibition (De Vry et al 1992). Unfortunately, as 
with most secondary health complications experienced by 
paralyzed individuals, depression and anxiety, although 
frequently reported after SCI, remain largely untreated 
(Smith et al 2007).
Activation of spinal locomotor 
networks by 8-OH-DPAT
Although a role of 5-HT in spinal motor control was pro-
posed several years ago (a facilitating role, see Jacobs and 
Fornal 1993), a determinant role in the control of locomotion 
per se has been demonstrated more recently (Schmidt and 
Jordan 2000; Jordan et al 2008). 5-HT was found indeed to 
trigger bouts of ﬁ  ctive locomotor rhythms (ie, bilaterally 
alternating and rhythmic ventral root-monitored activity) 
in in vitro isolated spinal cord preparations (mice, Jiang 
et al 1999; Nishimaru et al 2000; rats, Cazalets et al 1992). 
In vivo, transplantation of embryonic 5-HT cells or intrathe-
cal administration of 5-HT was also reported to promote 
the recovery of locomotor functions in SCI rats (Feraboli-
Lohnherr et al 1997, 1999; Ribotta et al 2000). Further 
supporting a determinant role of 5-HT in spinal locomotor 
activity, increased 5-HT release was measured in the lumbar 
cord using implanted microdialysis probes in freely moving 
animals during locomotion (Gerin et al 1995).
As mentioned earlier, recent data from this laboratory and 
others have provided convincing evidence of a speciﬁ  c role 
for 5-HTR1A in spinal locomotor rhythmogenesis (eg, Landry 
et al 2006). In vitro data from Hochman and colleagues (2001) 
have shown that bath application of 5-carboxamidotryptamine 
(5-CT, a 5-HTR1A/5A/7 agonist) combined with low doses of 
N-methyl-D-aspartate (NMDA: agonist at the corresponding 
glutamatergic receptor) elicited ﬁ  ctive locomotor rhythms 
in murine isolated spinal cord preparations. Other in vitro 
experiments have revealed that 5-HTR1A antagonists could 
block 5-HT-evoked fictive locomotion in neonatal rats 
(Cazalets et al 1992) and eliminate the afterhyperpolarization-
enhancing effect of 5-HT during fictive locomotion in 
lampreys (Wikstrom et al 1995). Altogether, results from in 
vitro isolated spinal cord preparations tend to suggest that 
spinal 5-HTR1A activation can induce and modulate CPG-
mediated rhythms in the mammalian spinal cord.
The above hypothesis has been conﬁ  rmed recently in 
in vivo models of SCI. For instance, chronic administration 
of 8-OH-DPAT (5-HTR1A agonist), alone or in combina-
tion with quipazine (5-HTR2A/2C agonist), was shown to 
signiﬁ  cantly improve the recovery of locomotor functions in 
low-thoracic Tx rats regularly trained on a treadmill (Antri 
et al 2003, 2005). We have recently found in low-thoracic 
Tx mice that 8-OH-DPAT can also acutely elicit short epi-
sodes of locomotor-like movements. Indeed, a single dose of 
8-OH-DPAT administered subcutaneously or intraperitone-
ally in untrained and otherwise non-stimulated Tx mice was 
found to induce bilaterally alternating hindlimb movements 
(Landry et al 2006). This ﬁ  nding has provided clear evidence 
that 5-HTR1A agonist administration can, in itself (without 
tail pinching, body weight-support assistance or other 
stimulation) activate CPG neurons and, hence, generate some 
hindlimb locomotor-like movements in complete paraplegic 
animals. This said, only partial CPG-activating effects were 
found in those experiments since the movements acutely 
induced by 8-OH-DPAT in Tx mice remained incomplete 
(ie, small amplitude rhythmic movements with no weight-
bearing and plantar foot placement capabilities). However, as 
reported in a number of in vitro studies, full CPG-activating 
effects may be obtained by combining several different types 
of ligands (eg, Jiang et al 1999; Whelan et al 2000) which, in 
turn, suggests that combinatorial drug treatments would fur-
ther enhance CPG activation and spinal stepping generation. 
This idea is supported also by evidence from in vivo models 
showing that greater (ie, larger amplitude or frequency) Neuropsychiatric Disease and Treatment 2008:4(4) 762
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hindlimb movements can be induced by combining several 
compounds (McEwen et al 1997; Guertin, 2004a, 2004b; 
Antri et al 2005; Guertin and Steuer 2005).
5-HTR1A and 5-HTR7-mediated 
effects induced by 8-OH-DPAT
We have recently established that 8-OH-DPAT-induced 
locomotor-like movements were comediated by both the 
5-HTR1A and 5-HTR7. Paraplegic mice pretreated with selec-
tive 5-HTR1A or 5-HTR7 antagonists were found indeed to 
display similar reductions of 8-OH-DPAT-induced move-
ments (Landry et al 2006). A complete blockade of 8-OH-
DPAT-induced movements was obtained in wild-type mice 
pretreated with both antagonists or in 5-HTR7-/- knock-outs 
pretreated with 5-HTR1A antagonists (Landry et al 2006) 
which, altogether, strongly supports the existence of a role for 
both receptor subtypes in spinal locomotor network activa-
tion. This conclusion is in line with data from other laborato-
ries that have also demonstrated a role of both 5-HTR1A and 
5-HTR7 in 8-OH-DPAT-induced control of body temperature 
and circadian rhythms (Hedlund et al 2004; Sprouse et al 
2004). A role of 5-HTR7 in CPG-mediated activity is also 
supported by in vitro data showing that 5-HTR7 antagonists 
can block electrically-evoked or 5-HT/NMDA-evoked ﬁ  c-
tive locomotion (Madriaga et al 2004; Liu and Jordan 2005; 
Pearlstein et al 2005).
Clinical relevance
As mentioned earlier, many SCI patients will develop severe 
health complications such as obesity, type II diabetes, car-
diovascular diseases, hormone dysregulation, muscle and 
bone loss, immune system deﬁ  ciencies, and life-threatening 
infections (Bauman et al 1999; Bauman and Spungen 
2000; Cruse et al 2000). While activity-based training 
(eg, manually-assisted training) may contribute to reduce 
secondary complications in incomplete SCI subjects (Heath 
and Fentem 1997; Hicks et al 2003; Ditor et al 2003, 2005; 
Martin Ginis et al 2008), it has generally failed to produce 
signiﬁ  cant effects in complete SCI patients (Harkema 2008). 
Given the ﬁ  ndings reported here, CPG-activating drugs may 
eventually become the ‘gold-standard’ to enhance the out-
come of activity-based training in complete SCI patients. This 
said, additional experiments and clinical trials clearly need 
to be performed in order to clarify a number of issues. For 
instance, it is unclear whether assisting-devices (eg, harness, 
robotic system, etc.) or functional electrical stimulation will 
be required in humans for the maintain of trunk stability and 
equilibrium (although not essential in mouse quadrupedal 
locomotion). It remains unclear also whether supraspinal (in 
incomplete SCI patients) or propriospinal input will contribute 
or interfer with drug-induced CPG activation in humans. None-
theless, the exciting results obtained in paraplegic mice suggest 
that CPG-activating drugs such as 5-HTR1A/7 agonists, may 
very well become effective treatments to trigger CPG activity 
and, hence, spinal stepping after SCI. It may thus be postulated 
that regular drug-induced training will partially reverse or 
prevent the development of secondary health complications 
since many of these problems are indeed related with chronic 
immobility after SCI (eg, cardiovascular problems, immune 
deﬁ  ciencies, osteoporosis, muscle atropy, etc.).
Concluding remarks
As mentioned earlier, 5-HTR1A agonists are better known as 
nonbenzodiazepine anxiolytics that can induce a short-term 
relief of anxiety with less side effects on sedation, depen-
dence and cognitive impairment than benzodiazepines. Data 
presented in this mini-review suggest the existence of a novel 
therapeutic application for 5-HTR1A agonists. In addition to 
treating anxiety and depression after SCI (brain-mediated 
presynaptic autoreceptor inhibition), they could eventually be 
part of a combinatorial drug treatment to reactivate locomotor 
circuits (spinal cord-mediated post-synaptic excitation/depo-
larization) in complete paraplegic or tetraplegic patients. If 
future clinical trials are to reveal safety and efﬁ  cacy for that 
novel indication, such treatment may eventually contribute to 
treat anxiety problems as well as immobility-related second-
ary health complications in chronic SCI patients.
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